Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Shijing Wang

Shijing Wang profile photo picture

Postdoctoral Researcher

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Hematology

image of /images/ORCIDiD_icon16x16.png   https://orcid.org/0009-0000-3187-944X


I am willing to collaborate on research projects.
I am willing to be a peer mentor.
I am willing to mentor a junior faculty member.

View Curriculum Vitae

Research Areas of Interest

  • Antigen-Antibody Reactions
  • Binding Sites, Antibody
  • Immunity
  • Immunity, Cellular
  • Nanospheres
  • Nanotechnology
  • Retinoblastoma

    • Publications (10)

  • An ultra-sensitive suboptimal protospacer adjacent motif enhanced rolling circle amplification assay based on CRISPR/Cas12a for detection of miR-183 (Zhiquan Lu, Shijing Wang, Ping Li, Huasheng Yang, Sanyang Han, Shaochong Zhang*, Lan Ma*) Frontiers in Bioengineering and Biotechnology 09/18/2024    
  • Bifunctional black phosphorus quantum dots platform: Delivery and remarkable immunotherapy enhancement of STING agonist. (Zhang Y, Wang S, Rha H, Xu C, Pei Y, Ji X, Zhang J, Lu R, Zhang S, Xie Z, Kim JS) Biomaterials 2024 Dec;311:122696 PMID: 38971121 SCOPUS ID: 2-s2.0-85197559694 07/07/2024       4 Citations
  • An anti-GD2 aptamer-based bifunctional spherical nucleic acid nanoplatform for synergistic therapy targeting MDM2 for retinoblastoma. (Wang S, Zhao Y, Yao F, Wei P, Ma L, Zhang S) Biomed Pharmacother 2024 May;174:116437 PMID: 38522240 SCOPUS ID: 2-s2.0-85188528328 03/25/2024       2 Citations
  • Lipid-nanoparticles-based co-delivery of black phosphorus quantum dots and melphalan by photothermal therapy combined with chemotherapy for retinoblastoma (Shijing Wang#*, Pengxue Wei, Yujun Zhang, Shaochong Zhang*) Polymer Testing 12/01/2023    
  • Prediction of Anticancer Peptides with High Efficacy and Low Toxicity by Hybrid Model Based on 3D Structure of Peptides. (Zhao Y, Wang S, Fei W, Feng Y, Shen L, Yang X, Wang M, Wu M) Int J Mol Sci 2021 May 26;22(11) PMID: 34073203 PMCID: PMC8198792 SCOPUS ID: 2-s2.0-85106414372 06/03/2021       10 Citations
  • Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models (Shijing Wang, Hui Wen, Wenyi Fei, Yuhong Zhao, Yuqi Feng, Lu Kuang, Min Wang*, Min Wu*) American Journal of Cancer Research 08/15/2020    
  • The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models. (Zhou R, Wang S, Wen H, Wang M, Wu M) Exp Cell Res 2019 Jul 15;380(2):141-148 PMID: 31034805 SCOPUS ID: 2-s2.0-85064756617 04/30/2019       17 Citations
  • The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models. (Wang S, Zhou R, Sun F, Li R, Wang M, Wu M) Cancer Lett 2017 Nov 28;409:125-136 PMID: 28923397 SCOPUS ID: 2-s2.0-85030263579 09/20/2017       12 Citations
  • A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growth. (Jia X, Wang W, Xu Z, Wang S, Wang T, Wang M, Wu M) Sci Rep 2016 Jun 15;6:27985 PMID: 27301650 PMCID: PMC4908374 SCOPUS ID: 2-s2.0-84974794732 06/16/2016       25 Citations
  • MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth (Zhuobin Xu, Zegen Wang, Xuelian Jia, Luxuan Wang, Zhiguo Chen, Shijing Wang, Min Wang, Juan Zhang, Min Wu*) Cancer Letters 03/01/2016    
    • Last update: 04/22/2025